Polysubstance Use Disorder

What is polysubstance use disorder?

Polysubstance use refers to the concurrent or sequential use of more than one psychoactive substance. In clinical and research contexts, it describes a pattern in which a person does not have a single primary substance of use but uses multiple substances, either simultaneously (combining two or more drugs in the same occasion) or in a rotating pattern (using different substances depending on availability, mood, or context).

The DSM-5 does not diagnose 'polysubstance use disorder' as a single entity. Rather, it requires clinicians to evaluate and diagnose each substance separately. A person who regularly uses alcohol, opioids, and benzodiazepines may receive three separate diagnoses. This matters because different substances require different treatment approaches: opioids have MAT; benzodiazepines require a supervised taper; alcohol withdrawal requires its own medical management. Treatment plans that address only one substance while others continue in use are incomplete and less effective.

Polysubstance use is the norm rather than the exception in addiction treatment populations. Research consistently shows that the majority of people entering addiction treatment are using more than one substance. Among people with opioid use disorder, alcohol and benzodiazepines are frequently co-used. Among people with alcohol use disorder, benzodiazepines and stimulants are commonly co-occurring. Among people who use stimulants, opioids are increasingly co-present given the fentanyl-contamination of the broader drug supply.

In Monmouth County and across the Jersey Shore, the polysubstance picture reflects national trends while carrying local features: the fentanyl-contaminated heroin and cocaine supply means that many people are unknowingly using opioids alongside their intended drug, with lethal consequences. The combination of alcohol and opioids in a culture where both are socially normalized and widely available is a persistent driver of preventable overdose in this region.

Why combining drugs is more dangerous than using one alone

Drug interactions in the body are not simply additive. When two substances act on overlapping systems, the combined effect is often synergistic, meaning greater than the sum of the parts, and frequently unpredictable. Understanding the most dangerous common combinations is clinically important.

Depressant combinations are the most acutely lethal class of interaction. Opioids, benzodiazepines, alcohol, and other CNS depressants all suppress the respiratory drive. When two or more are combined, the suppression of breathing is synergistic: a dose of each that would not cause dangerous respiratory depression independently can, in combination, reduce the drive to breathe to the point of fatal hypoxia. This mechanism accounts for a large proportion of opioid overdose deaths. Many people who die of opioid overdose have detectable benzodiazepines or alcohol in their system at autopsy.

The opioid-benzodiazepine combination warrants explicit emphasis because it is both extremely common in treatment populations and extremely dangerous. The FDA has issued a black box warning against concurrent use of both classes. Despite this, the combination is prevalent because both classes are widely prescribed and the patients who have anxiety disorders and chronic pain, the populations most likely to receive both, are the populations with the highest rates of both disorders.

Stimulant-depressant combinations present a different risk profile. A person using cocaine or methamphetamine with opioids may not feel the full sedating effect of the opioid because the stimulant is masking it. This masking can lead to taking more of both drugs than would be safe, and when the stimulant wears off first (as cocaine's shorter half-life often produces), the person is left with the full opioid load and no stimulant compensation, which can cause sudden respiratory depression.

The alcohol-cocaine combination produces a distinct pharmacological entity, cocaethylene, formed in the liver. Cocaethylene has a longer half-life than cocaine and augments cardiovascular toxicity. It is associated with increased risk of sudden cardiac death compared to either substance alone.

The intentional or unintentional combination of multiple drugs also complicates overdose recognition and response. An unconscious person who has used multiple substances may not respond to naloxone alone if stimulants, alcohol, or benzodiazepines are also involved, because naloxone only reverses opioid effects. Emergency responders may need to manage multiple drug effects simultaneously.

Physical and psychological signs of polysubstance use

The signs of polysubstance use disorder reflect the combined and sometimes contradictory effects of multiple substances. A person using both stimulants and depressants may cycle through periods of agitation and high energy followed by sedation and slowed response, in patterns that do not clearly match the profile of any single substance.

• Using multiple substances to manage the effects of others, for example using alcohol to come down from cocaine, or opioids to manage stimulant-induced anxiety
• Combining substances in fixed patterns, such as always using alcohol with opioids or benzos with cocaine
• Unpredictable or extreme intoxication states that do not correspond to any single substance's expected effects
• Multiple withdrawal syndromes presenting simultaneously or in sequence when attempting to stop
• Difficulty stopping any one substance because of its interaction with the others in the pattern
• Higher overdose risk and a history of near-misses or overdose survivals
• Inability to identify a single 'primary' substance, which complicates self-referral and treatment entry
• Financial and social problems compounded by the cost and behavioral impact of multiple substances
• Medical complications reflecting multiple substance effects: liver damage from alcohol, cardiovascular stress from stimulants, and opioid effects on the GI and respiratory systems simultaneously
• Cognitive impairment reflecting the cumulative effects of multiple substances on multiple neurotransmitter systems

Polysubstance use and the fentanyl contamination problem

The current fentanyl-contaminated drug supply has created a new category of unintentional polysubstance use that warrants explicit discussion. An unknown but substantial proportion of people who present with what they believe is cocaine, methamphetamine, or even MDMA use are now also being exposed to fentanyl, because the supply chains that distribute these substances are contaminated with fentanyl at various points.

This means that people with no opioid tolerance who have never intentionally used opioids are receiving potentially lethal doses of fentanyl mixed into stimulants, pressed pills, or powders. They do not experience the warning signs of sedation that a person with opioid tolerance might notice, and they may collapse without warning. This is one of the drivers of overdose deaths in young adults who are described as not having had a known opioid problem.

Naloxone should be in the hands of every person who uses any illicit substance, not only people who intentionally use opioids. Fentanyl test strips can detect the presence of fentanyl in a drug supply before use. Both are available at pharmacies and harm-reduction programs throughout New Jersey. Fear of legal consequences should not prevent calling 911 in an overdose emergency; New Jersey's Good Samaritan Law provides protection.

The withdrawal complexity of polysubstance dependence

Managing withdrawal from multiple substances simultaneously is one of the most clinically complex aspects of polysubstance use disorder. The medical risks and timelines of withdrawal differ by substance, and they can interact in dangerous ways.

Alcohol and benzodiazepine withdrawal both carry seizure risk and can be life-threatening. When a person is dependent on both, the withdrawal management must account for both. The clinical protocol typically uses benzodiazepines to manage alcohol withdrawal, which requires careful adjustment when the person is also dependent on benzodiazepines.

Opioid withdrawal, while extremely uncomfortable, is not typically life-threatening for otherwise healthy adults. But opioid withdrawal combined with alcohol withdrawal, or with the crash phase following stimulant discontinuation, produces a composite clinical picture that may require more intensive medical management.

This complexity is the clinical reason why polysubstance use disorder requires a thorough medical evaluation before and during detox, and why self-managed withdrawal from multiple substances, especially those involving alcohol or benzodiazepines, is inadvisable. Archangel coordinates with medical detox partners to ensure clients with complex polysubstance dependence access appropriate medical management before entering our outpatient programs.

Treatment for polysubstance use disorder

Effective treatment for polysubstance use disorder addresses every substance in use, not just the primary complaint. Treatment that successfully manages opioid dependence but ignores concurrent alcohol use disorder, for example, leaves a significant relapse risk in place and fails to adequately serve the client.

The treatment framework applies the appropriate evidence-based approach to each substance class. For opioids, MAT with buprenorphine or naltrexone is integrated alongside behavioral therapy. For alcohol or benzodiazepine dependence, medical detox or supervised taper precedes behavioral treatment. For stimulant use disorder, CBT and contingency management are the primary modalities. When all are present, the treatment plan coordinates these approaches in a way that is clinically coherent and logistically manageable for the person in treatment.

Co-occurring mental health conditions are even more prevalent in polysubstance use disorder populations than in single-substance disorders. Trauma, depression, anxiety, PTSD, and ADHD are all more common when multiple substances are involved. The clinical picture is often that the substances were recruited at different times to manage different aspects of unaddressed mental health needs. Integrated dual-diagnosis treatment is not optional in this population; it is the standard of quality care.

Motivational work is particularly important in polysubstance use disorder because identifying a single primary substance to focus on is often impossible, and the interaction between substances can make it harder to recognize the full extent of the problem. Motivational interviewing, which meets the person where they are and works with their own values and priorities, is especially useful at treatment entry.

Polysubstance treatment at The Archangel Centers: Monmouth County, NJ

The Archangel Centers provides licensed outpatient addiction treatment for polysubstance use disorder at 44 Apple St STE 3, Tinton Falls, NJ. We serve Monmouth County and the Jersey Shore, with clients from Red Bank, Asbury Park, Long Branch, Neptune, Freehold, and surrounding communities.

Our clinical intake process includes a thorough assessment of all substances in use, not just the presenting concern. This drives a treatment plan that addresses the full picture. When medical detox is needed for alcohol, benzodiazepines, or opioid dependence, we coordinate with medical partners before program entry.

PHP (Partial Hospitalization Program): Intensive daily clinical programming appropriate for clients with multiple active substance dependencies, significant co-occurring psychiatric conditions, or unstable life circumstances. PHP provides the clinical contact density to manage complex presentations while maintaining community connection.

IOP (Intensive Outpatient Program): Three or more days per week. The primary level of care for most people beginning recovery from polysubstance use disorder. Group therapy addresses multiple substances, individual counseling is tailored to the person's full profile, and MAT coordination is available for clients with opioid or alcohol use disorder.

Standard Outpatient (OP): For clients in stable recovery across all substances, ongoing accountability and clinical support.

Most major insurance plans and New Jersey Medicaid cover our levels of care. Benefits are verified before admission.

What recovery from polysubstance use disorder looks like

Recovery from polysubstance use disorder is more complex than single-substance recovery, but it is not less possible. The complexity lies in coordinating the biological, psychological, and behavioral recovery from multiple substances simultaneously, each of which has its own neurobiological footprint and its own recovery timeline.

The early period can be particularly disorienting. Removing multiple substances at once may reveal mental health symptoms that were masked by the drug use, and it takes time to distinguish drug-induced psychiatric symptoms from underlying conditions. Sleep is often severely disrupted. Mood is unstable. The clinical support of a structured program is more important, not less, in this context.

With time and consistent engagement, the picture clarifies. Clients begin to understand their own patterns, the conditions they were self-medicating, the triggers that drove use, the substances that played what roles. This understanding, combined with the skills to manage those conditions differently, is the foundation of durable recovery.

The Archangel Centers team holds a great deal of experience with exactly this presentation. The Jersey Shore community has high rates of polysubstance use, and our clinical program is designed to address the full picture. If you are using more than one substance and wondering whether treatment is possible for you specifically, call us. It is. This is exactly what we do.